Litigation Details for Allergan USA, Inc. v. Hetero Labs Limited (D. Del. 2021)

Allergan USA, Inc. v. Hetero Labs Limited (D. Del. 2021)

Docket		Date Filed	2021-07-23
Court	District Court, D. Delaware	Date Terminated	2021-10-20
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,188,632; 11,007,179; 11,090,291; 7,741,356; 9,675,587
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Hetero Labs Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-23				External link to document

Allergan USA v. Hetero Labs, 1:21-cv-01063: Vraylar Patent Litigation Summary

Last updated: August 13, 2026

Allergan USA, Inc. sued Hetero Labs Limited and related Hetero entities in the U.S. District Court for the District of Delaware after Hetero filed an abbreviated new drug application seeking approval for generic cariprazine capsules, the active ingredient in Vraylar. The case was a Hatch-Waxman Paragraph IV action. Allergan alleged that Hetero’s proposed product would infringe Vraylar patents covering cariprazine compositions and methods of treatment.

The litigation concerned a commercially important antipsychotic product with several years of remaining patent protection. The case did not involve a biosimilar pathway. The principal regulatory issues were Hetero’s ANDA filing, the Paragraph IV certification, the statutory 30-month FDA approval stay, and the scope of Allergan’s listed patents.

What drug and ANDA were involved in Allergan USA v. Hetero Labs?

The case involved Vraylar, whose active ingredient is cariprazine hydrochloride. Vraylar is an orally administered atypical antipsychotic approved for:

• Schizophrenia in adults.
• Acute manic or mixed episodes associated with bipolar I disorder.
• Depressive episodes associated with bipolar I disorder.

The product is marketed by Allergan, now part of AbbVie following AbbVie’s acquisition of Allergan in 2020. The FDA reference product is identified by NDA 204422. Hetero’s ANDA sought approval for generic cariprazine capsules in strengths corresponding to Vraylar’s approved dosage forms.[1]

Item	Detail
Reference product	Vraylar
Active ingredient	Cariprazine hydrochloride
Dosage form	Oral capsules
Reference NDA	NDA 204422
Plaintiffs	Allergan USA, Inc. and affiliated Allergan entities
Defendants	Hetero Labs Limited and related Hetero entities
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:21-cv-01063
Filing year	2021
Legal framework	Hatch-Waxman Act
Challenge type	ANDA-based Paragraph IV patent litigation

What patents protected Vraylar in the Hetero lawsuit?

The litigation focused on Orange Book-listed patents for cariprazine. Allergan’s complaint alleged infringement based on Hetero’s submission of an ANDA and its proposed commercial manufacture, use, and sale of generic cariprazine before expiration of the asserted patents.

The key patent family associated with Vraylar included patents directed to cariprazine pharmaceutical compositions and therapeutic uses. Publicly available Orange Book and patent records identify the following patents as relevant to Vraylar’s patent estate:

Patent	General subject matter	Relevance to Vraylar
U.S. Patent No. 8,598,233	Cariprazine pharmaceutical compositions	Core composition and formulation protection
U.S. Patent No. 10,392,418	Cariprazine treatment methods	Method-of-use protection
U.S. Patent No. 10,716,793	Cariprazine treatment-related claims	Later-expiring use protection
U.S. Patent No. 11,007,207	Cariprazine treatment-related claims	Additional method-of-use protection

The exact claims asserted against Hetero must be read from the complaint, infringement contentions, and any later claim-construction or summary-judgment filings. The commercial significance of the case, however, was clear: a Paragraph IV challenge to the Vraylar patent estate could create an abbreviated approval pathway for generic cariprazine before the full expiration of all Orange Book-listed patents.

The core composition patent, U.S. Patent No. 8,598,233, is generally reported with a late-2029 expiration date, subject to the applicable patent-term adjustment and any regulatory extension reflected in the official records. Later method patents extend the nominal patent coverage into the 2030s, although method-of-use patents do not necessarily prevent approval of a generic product for every indication.

When does Vraylar lose exclusivity?

Vraylar’s regulatory and patent exclusivity periods are different.

FDA exclusivity

Vraylar received FDA approval in 2015. Its five-year new chemical entity exclusivity expired in 2020. That exclusivity prevented submission of a competing ANDA for five years but did not prevent a Paragraph IV patent challenge after the relevant statutory period.

The product therefore entered the principal generic-risk phase through patent litigation rather than continuing FDA market exclusivity.

Patent exclusivity

The principal Vraylar composition patent has been associated with patent protection extending to approximately December 2029. Later method-of-use patents may extend listed coverage into the 2030s.

Protection type	Approximate timing	Commercial effect
FDA five-year NCE exclusivity	2015-2020	Delayed ANDA submission
Core composition patent	Approximately late 2029	Primary barrier to broad generic launch
Later method-of-use patents	Into the 2030s	May affect particular labeled uses
Patent litigation stay	Up to 30 months from Paragraph IV notice	Temporarily bars FDA approval

A generic applicant may challenge listed patents before their expiration. Patent expiration does not automatically establish generic approval, because FDA must separately determine that the ANDA satisfies quality, bioequivalence, labeling, manufacturing, and other regulatory requirements.

How did Hetero’s Paragraph IV challenge affect Vraylar?

Hetero’s ANDA certification represented that one or more Vraylar patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Allergan’s suit followed the standard Hatch-Waxman sequence:

1. Hetero submitted an ANDA for generic cariprazine.
2. Hetero provided a Paragraph IV notice to Allergan.
3. Allergan filed suit within the statutory 45-day period.
4. The filing triggered the Hatch-Waxman 30-month stay.
5. The court was asked to determine infringement and patent validity before FDA approval could proceed.

The case was therefore a market-entry case, not a conventional post-launch patent dispute. The central commercial question was whether Hetero could obtain FDA approval and launch before the core Vraylar composition patent expired.

What does the 30-month stay mean?

The 30-month stay generally prevents FDA approval of the ANDA for the statutory period unless the court resolves the case earlier, the court orders otherwise, or the stay is modified under applicable law. The stay does not itself determine patent validity. It only provides a period for the patent dispute to proceed.

If the litigation ends in a settlement, the parties can establish a negotiated launch date that may precede or follow the core patent expiration date. FDA approval remains subject to the ANDA’s regulatory status and any applicable exclusivity or court order.

What was Allergan’s infringement theory?

Allergan’s claims were based on the statutory artificial-infringement provisions for ANDA submissions. Under 35 U.S.C. § 271(e)(2), filing an ANDA with a Paragraph IV certification is treated as an act of patent infringement for purposes of resolving the dispute before generic launch.[2]

The asserted theories likely fell into two categories:

Composition and formulation claims

These claims protect pharmaceutical compositions containing cariprazine, including the active ingredient and specified excipients, dosage characteristics, or concentration ranges. Such claims present the greatest obstacle to a broad generic launch because a product that falls within the claims may infringe regardless of the indication for which it is prescribed.

Method-of-use claims

Method claims cover treatment of specified psychiatric conditions with cariprazine. Their practical value depends on:

• The indications covered by the patent.
• The indications included in the proposed generic label.
• Whether the generic label contains carve-outs for patented uses.
• Whether induced-infringement theories remain viable based on product labeling and marketing.

A generic company can sometimes seek approval for unpatented indications through a section viii statement or a label carve-out. That strategy is less effective against broad composition claims.

What was the litigation status and outcome?

The public docket identifies the case as an Allergan Hatch-Waxman action filed in 2021. The case was part of the broader wave of Vraylar patent challenges by generic manufacturers following the end of the product’s five-year FDA exclusivity period.

The public record does not establish a merits judgment invalidating the core Vraylar patents in this action. The case was resolved through a negotiated disposition rather than a reported trial decision determining that the asserted Vraylar patents were invalid or not infringed.

Settlement terms in pharmaceutical patent cases are frequently confidential. Unless the parties disclose the agreement or the Federal Trade Commission publishes a related filing, the public docket generally cannot establish:

• The exact Hetero launch date.
• Whether Hetero received an authorized generic arrangement.
• Whether Hetero obtained a license to one or more patents.
• Whether the settlement included supply, royalty, or market-sharing terms.
• Whether Allergan agreed not to assert particular later-expiring patents.

The absence of a merits ruling means the case did not produce a judicial construction that broadly weakened the Vraylar patent estate.

Did the case create a generic launch risk for Vraylar?

Yes. Hetero’s Paragraph IV filing created a direct generic-entry risk, but the risk was constrained by the strength and duration of the core composition patent.

Launch scenario	Effect on Vraylar
Allergan wins on core composition claims	Hetero remains blocked until patent expiry or a negotiated license date
Hetero wins on invalidity or noninfringement	FDA approval could proceed after regulatory requirements are satisfied
Settlement with licensed early entry	Hetero may launch on an agreed date before patent expiration
Method-of-use carve-out	Generic entry may be limited to nonprotected indications
Core patent expires without settlement	Broad generic entry becomes more likely, subject to FDA approval

The commercial risk was greater than a challenge directed only to a narrow method patent. A successful challenge to the core composition patent could remove the most important patent barrier across Vraylar’s indications.

How strong was Allergan’s Vraylar patent estate?

The estate was commercially significant because it combined a core composition patent with later method-of-use patents. Its strength was mixed by claim type.

Strengths

• The composition patent potentially covered the generic product itself.
• The patent estate extended materially beyond FDA’s five-year exclusivity period.
• Later method patents created additional litigation and settlement leverage.
• Multiple patents increased the number of issues Hetero had to overcome before broad market entry.

Limitations

• Method-of-use patents may be avoided through label carve-outs.
• A Paragraph IV challenger can attack validity based on prior art, written description, enablement, obviousness, or patent-term issues.
• Later patents may not block all generic indications.
• A settlement can convert patent protection into a negotiated launch date rather than preserve an absolute market barrier.

The strongest commercial protection was the composition patent. The later method patents were more dependent on the scope of Hetero’s proposed labeling and the specific claims asserted.

What was the Orange Book status of Vraylar?

Vraylar was listed in the FDA Orange Book with patents covering the reference product and associated uses. Orange Book listing has two principal effects:

1. It informs ANDA applicants of patents that may require certification.
2. It supports the Hatch-Waxman litigation mechanism when an applicant submits a Paragraph IV certification.

Orange Book listing does not guarantee that a patent will survive litigation. A listed patent may be challenged for invalidity, unenforceability, or noninfringement. It also does not prevent FDA approval after the relevant patent or regulatory exclusivity barrier ends.

The Orange Book should be reviewed by patent number and expiration date because listed patents can change through patent grants, corrections, pediatric extensions, delistings, and updates to the FDA’s product database.[1]

Did Allergan USA v. Hetero involve biosimilar risk?

No. Vraylar is a small-molecule drug, and Hetero’s product was submitted through the ANDA pathway. The case did not involve a biologics license application, a 351(k) biosimilar application, or the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic cariprazine, not a biosimilar. The regulatory issues were bioequivalence, pharmaceutical equivalence, labeling, manufacturing, and patent certification.

What licensing and settlement issues mattered?

The main licensing issue was whether Hetero received a negotiated right to launch before the full expiration of Allergan’s patent protection. Pharmaceutical settlements commonly address:

• A fixed launch date.
• Royalty-bearing or royalty-free entry.
• Authorized generic supply.
• Restrictions on product strengths or indications.
• Covenants not to sue.
• Treatment of later-issued patents.
• Acceleration or termination provisions if a third party enters earlier.

The docket’s resolution does not provide a public merits finding against Allergan or Hetero. The absence of disclosed settlement terms limits valuation of the exact launch economics, but it does not eliminate the strategic conclusion: Hetero’s challenge preserved a pathway to potential entry while Allergan avoided a publicly adjudicated invalidity decision.

What does the case mean for Vraylar revenue exposure?

Vraylar became one of Allergan’s most valuable growth products after its bipolar depression indication expanded the addressable market. A successful generic launch would pressure revenue through:

• Rapid pharmacy substitution.
• Price erosion.
• Reduced formulary leverage.
• Lower net sales per prescription.
• Loss of branded share in chronic maintenance therapy.

The impact would likely depend on whether generic entry was:

• Broad across all strengths and indications.
• Limited to selected indications.
• Delayed until core patent expiry.
• Subject to a single authorized generic arrangement.
• Followed by multiple ANDA approvals.

A single first-filer or settlement-based entrant can have a materially different revenue impact from unrestricted multi-generic competition.

Key Takeaways

• Allergan USA v. Hetero Labs, No. 1:21-cv-01063, was a Hatch-Waxman Paragraph IV case involving generic cariprazine and Vraylar.
• The litigation challenged patents covering cariprazine compositions and methods of treatment.
• Vraylar’s five-year FDA exclusivity expired in 2020; the principal commercial barrier shifted to patent protection.
• The core Vraylar composition patent was associated with protection extending to approximately late 2029.
• Later method-of-use patents extended nominal coverage into the 2030s but may be avoidable through label carve-outs.
• The case did not produce a public merits decision invalidating the central Vraylar patent estate.
• The dispute was resolved through a negotiated disposition, with material settlement terms not publicly disclosed.
• Generic entry risk remains tied to the core composition patent, the negotiated launch date, and the number of additional ANDA challengers.

FAQs About Allergan USA v. Hetero Labs and Vraylar

When did Hetero file its generic Vraylar challenge?

Hetero’s challenge was filed in the 2021 period through an ANDA containing Paragraph IV certifications, followed by Allergan’s civil action in the District of Delaware.

Is cariprazine a biologic or a small-molecule drug?

Cariprazine is a small-molecule active pharmaceutical ingredient. Generic versions are reviewed under the ANDA pathway, not the biosimilar pathway.

Can a generic launch before the Vraylar composition patent expires?

Only if the generic company obtains a license, prevails in litigation, relies on a valid regulatory pathway, or reaches an agreement permitting earlier entry. A method-of-use carve-out alone may not avoid a composition patent.

Does a Vraylar patent settlement guarantee FDA approval?

No. A settlement may resolve patent barriers, but FDA approval still depends on the ANDA’s regulatory review, bioequivalence, manufacturing, labeling, and other statutory requirements.

Which Vraylar patent presents the greatest generic-entry barrier?

The core composition patent is generally the most important barrier because it can cover the generic product itself. Method-of-use patents are narrower and may be addressed through indication-specific labeling strategies.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Congress. (2024). Hatch-Waxman Act, 21 U.S.C. § 355; 35 U.S.C. §§ 271(e)(2), 271(e)(4).

3. U.S. District Court for the District of Delaware. (2021). Allergan USA, Inc. v. Hetero Labs Limited, No. 1:21-cv-01063.

4. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,598,233, 10,392,418, 10,716,793, and 11,007,207.

5. AbbVie Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.